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Background: An involvement of the renin angiotensin system in atrial fibrillation (AF) has been hypothesized, and ACE DD genotype has
been suggested to influence the predisposition to AF. The aim of this study was to investigate the role of the ACE I/D polymorphism in
relation to the different clinical forms of AF, lone and secondary nonvalvular atrial fibrillation (NVAF).
Methods: 510 consecutive patients with documented NVAF (106 patients had lone, and 404 secondary NVAF), and 520 controls with a
negative history of cardiovascular disease have been studied.
Results: A significant difference in allele frequency between lone and secondary NVAF ( p=0.002) has been found. The ACE D allele was
associated with the predisposition to lone NVAF under a dominant, recessive and additive model, both at univariate and multivariate analysis,
after adjustment for age and gender (multivariate analysis: dominant OR=2.87, p=0.02; recessive OR=2.01, p=0.003; additive OR=4.47,
pb0.0001). ACE D allele was significantly associated with secondary NVAF at both univariate and multivariate analysis under a recessive
and additive, but not dominant, model (multivariate analysis: recessive OR=1.89, p=0.001; additive OR=2.50, pb0.0001).
Conclusions: This study highlights the role of ACE gene in predisposing to both lone and secondary NVAF, further contributing to penetrate
the genetic mechanisms responsible for this complex disease. The clinical relevance of our results may be related to the possible
characterization of subjects predisposed to NVAF in the absence of traditional risk factors, and to the use of ACE-inhibitors therapy able to
improve the arrhythmogenic substrate.
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Nonvalvular atrial fibrillation (NVAF) is the commonest
cardiac arrhythmia in clinical practice and is associated with
substantial morbidity and mortality. Its incidence and
prevalence are increasing, and it represents a potential
cause of thromboembolic events [1]. Independent risk⁎ Corresponding author. Tel.: +39 0557949420; fax: +39 0557949418.
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doi:10.1016/j.ijcard.2006.08.079factors include male sex, increasing age, hypertension,
thyroid disease, diabetes, smoking habit, valvular heart
disease, and myocardial infarction [2], besides left atrial
dilation and left ventricular hyperthrophy [3]. Nevertheless,
the molecular basis for the development of structural
remodeling of human atria is still a matter of investigation.
There are increasing information on the relevance of
investigating polymorphisms in candidate genes for atrial
fibrillation (AF), in order to evaluate their influence on
susceptibility to this complex condition. Genetic case-
Table 1
Demographic and clinical characteristics of the study population
Variable Patients
(n=510)
Healthy subjects
(n=520)
P-value
Age (years) a 71.3±10.2 70.1±13.0 0.07
Males, n (%) 312 (61.2) 326 (62.7) 0.6
Females, n (%) 198 (38.8) 194 (37.3) 0.6
Hypertension, n (%) 308 (60.4) 119 (22.9) b0.0001
Dyslipidemia, n (%) 113 (22.2) 86 (16.5) 0.04
Diabetes, n (%) 85 (16.7) 22 (4.2) b0.0001
Smoking habit, n (%) 128 (25.1) 87 (16.7) 0.001
CAD (%) 114 (22.4) –
Left atrial dimension
N38 mm (%)
427 (83.7) –
LVEFb50% (%) 169 (33.1) –
ACE-Inhibitor (%) 109 (21.4) 12 (2)
β-blocker (%) 20 (4) 2 (0.4)
Angiotensin receptor
antagonist (%)
30 (6) 2 (0.4)
Calcium antagonist (%) 49 (10) 1 (0.2)
Diuretic (%) 90 (18) 1 (0.2)
Digoxin (%) 104 (20) –
Statin (%) 23 (5) –
Aspirin (%) 118 (23) –
Oral anticoagulant (%) 25 (5) –
Antiarrhythmic (%) 58 (11) –
Oral antidiabetes (%) 31 (6.1)
a Continuous data are presented as mean±SD; CAD = coronary artery
disease; LVEF = left ventricular ejection fraction.
Table 2
ACE I/D polymorphism in subjects receiving ACE-inhibitors therapy
ACE I/D polymorphism Patients (n=109) Healthy subjects (n=12)
DD 44 (40.4) 5 (41.7)
ID 51 (46.8) 5 (41.7)
II 14 (12.8) 2 (16.6)
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phenotype and genotype and represent the most common
studies used to evaluate the genetic basis of disease
predisposition. Some polymorphisms have functionally
significant effects on the gene product and they represent
the most useful type of polymorphisms in disease association
studies.
In the intron 16 of the gene encoding for the angiotensin
converting enzyme (ACE), a polymorphism consisting of an
insertion/deletion (I/D) of a 287-bp fragment has been
identified [4], and the ACE D allele has been reported to be
associated with increased serum levels of circulating enzyme
[5]. The ACE DD genotype is associated with higher plasma
levels of the enzyme, the II genotype with lower ACE levels,
and the ID genotype with intermediate levels [5]. Data from
experimental studies reported both a functional role for the
ACE I/D polymorphism in modulating angiotensin II levels
[6], and an increased mRNA expression in white blood cells
from subjects carrying the ACE D allele in comparison to
subjects carrying the I allele [7].
The ACE I/D is an appealing polymorphism in relation to
susceptibility to cardiovascular diseases, including hyper-
tensive heart disease [8], congestive heart failure [9],
coronary artery disease [10], and cardiomyopathy [11]. An
involvement of the renin angiotensin system (RAS) in AF
has been suggested, due to the finding of increased ACE
expression in the atrial tissue of patients with AF [12].
Angiotensin II can induce via activation of mitogen activated
protein kinases, such as Erk1/Erk2, the proliferation offibroblasts as well as extracellular matrix protein accumu-
lation [13], and it has been hypothesized that the demon-
strated activation of the Erk pathway within the atrial
interstitium may be one molecular mechanism explaining
fibrotic changes of the atrial tissue in patients with AF.
We previously showed a role for the ACE DD genotype as
a predisposing factor to AF in 148 patients with persistent
AF compared with 210 healthy controls [14].
The aim of this report was to investigate the influence of
ACE I/D polymorphism in relation to the clinical forms of
lone and secondary NVAF, in a larger population.
2. Materials and methods
2.1. Study population
The study population consisted of 510 consecutive
hemodynamically stable patients with documented NVAF
lasting N24 h without periods of sinus rhythm (mean
duration 5±0.4 weeks, as documented by electrocardiogra-
phy) referred to the Division of Cardiology, University of
Florence, Careggi Hospital, Florence, and 520 control
subjects, comparable for age and gender, invited to
participate in the study, and consisted of partners or friends
of patients, and healthy subjects from a population study
“Progetto Nutrizione per la Salute e la Prevenzione di
Malattia” conducted between 2002 and 2004 in Florence,
Italy. Exclusion criteria for the controls were: personal and
family history of cardiovascular disease. A detailed inter-
view addressed to personal and familial history was
performed in the frame of a physical examination by expert
physicians, in order to identify symptom-free subjects and to
exclude those who were suspected of having any form of
vascular disease. Moreover, we accurately interviewed our
control subjects, in order to identify the existence of
symptoms related to arrhythmias.
For all subjects a 12-lead ECG, 24-h ECG recordings,
stress-test, chest roentgenogram, routine laboratory screen-
ing, thyroid function test, and echocardiography were
obtained. Transthoracic echocardiography was performed
to measure left atrial dimension. In particular, in patients
showing symptoms related to the presence of cardiovascular
disease, a more accurate clinical and instrumental evaluation
was performed (e.g. echo-stress testing, myocardial scintig-
raphy, and/or coronarography).
For the inclusion in the current study, all subjects needed
to have performed one or more complete echocardiographic
examinations. All of the original echocardiographic data
Table 3
Genotype distribution and allele frequencies of ACE I/D polymorphism
Genotype Allele All
patients
Lone AF
patients
Secondary AF
patients
Healthy
subjects
Distribution Frequency (n=510)
(%)
(n=106)
(%)
(n=404) (%) (n=520)
(%)
ACE II 70
(13.7)
9 (8.5) 61 (15.1) 126
(24.2)
ACE ID 218
(42.7)
49 (46.2) 169 (41.8) 251
(48.3)
ACE DD 222
(43.5)
48 (45.3) 174 (43.1) 143
(27.5)
ACE D 0.65 a 0.68 b 0.64 0.52
a ACE D frequency in all NVAF patients vs. healthy subjects, pb0.0001;
genotype distribution pb0.0001.
b ACE D frequency in lone NVAF patients vs. secondary NVAF patients,
p=0.002; genotype distribution p=0.2.
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dilation and ejection fraction.
Exclusion criteria for patients included one of the
following: familial AF, hyperthyroidism, valvular heart
disease, including mitral valve prolapse, symptomatic heart
failure, cardiomyopathy, chronic obstructive pulmonary
disease, cardiomegaly apparent on the chest radiography,
AF due to trauma, surgery, or acute medical illness. The
number of patients initially assessed for inclusion into the
study was 632. One-hundred and twelve patients were
ineligible for inclusion after initial assessment as 28 had
thyroid disease, 24 valvular heart disease, 26 symptomatic
heart failure, 11 cardiomyopathy, 15 pulmonary disease, and
8 a familial history of AF. Moreover, 10 AF patients refused
to assent with the genetic analysis.
Patients who were younger than 65 (years) and had no
identifiable cause of AF were classified as lone NVAF
patients.
The presence of traditional cardiovascular risk factors was
assessed on the basis of patients' interview, echocardiogra-
phy data and hospital records. Current smoking status was
determined at the time of blood collection. The subjects were
considered to have hypertension according to the guidelines
of the European Society of Hypertension/European SocietyTable 4
Univariate analysis for ACE I/D polymorphism according to dominant, recessive
Variable Odds ratios
Age 1.007 (0.99
Gender 0.95 (0.71
Hypertension 10.54 (7.72
Diabetes 5.72 (3.48
Smoking habit 2.31 (1.70
Dyslipidemia 1.53 (1.21
ACE I/D
polymorphism
Dominant model Recessive m
Odds ratios (95% CI) P Odds ratios
Lone NVAF 2.89 (1.21–6.04) 0.02 2.18 (1.40–
Secondary NVAF 1.44 (0.95–2.19) 0.08 1.99 (1.51–of Cardiology [15] or if they were taking antihypertensive
drugs. Dyslipidemia was defined according to the Third
report of the National Cholesterol Education Program
(NCEP) [16], and diabetes in agreement with the American
Diabetes Association [17].
Coronary heart disease was defined on the basis of a
history of myocardial infarction or stable and unstable
angina. Left atrial dilation was defined as a diameter N38
mm at echocardiography [18], and left ventricular dysfunc-
tion was defined as ejection fraction b50%.
All subjects in the patient and control group were
Caucasian, unrelated to each other, and resident in the
same geographic area. All subjects gave informed consent
and the study complies with the Declaration of Helsinki and
was approved by the local ethic committee.
2.2. Molecular analysis
Genomic DNA extraction was performed from peripheral
blood leucocytes by using a QIAmp Blood Kit (QIAGEN,
Hilden, Germany).
The ACE I/D polymorphism was genotyped according to
previously reported methods [19].
ACE I/D polymorphism was evaluated through PCR
reaction, carried out in a PCR thermocycler (MJ Research) at
anannealing temperatureof58°C,according toRigat etal. [20].
The reaction was performed in a final volume of 15 μl with
0.2 mM of each dNTP, 5% DMSO, MgCl2 3 mM, 4 pmol of
forward primer (5′-CTGGAGACCACTCCCATCCTTTCT-
3′), 4 pmol of reverse primer (5′-GATGTGGCCATCA-
CATTCGTCAGAT-3′, 0.5 U of Taq polymerase (GoTaq,
Promega Italia, Milano, Italy) in PCR 1X buffer. ACE DD
genotypesamplesweresubjected toasecondPCRreactionatan
annealing temperature of 67 °C in order to specifically amplify
the I allele [19].
2.3. Statistical analysis
Statistical analysis was performed by using the SPSS
(Statistical Package for Social Sciences, Chicago, USA)
software for Windows (Version 11.5). Continuous variablesand additive genetic models
(95% CI) P
–1.02) 0.4
–1.26) 0.7
–14.31) b0.0001
–9.32) b0.0001
–3.21) b0.0001
–2.14) 0.007
odel Additive model
(95% CI) P Odds ratios (95% CI) P
3.51) b0.0001 4.69 (2.22–9.96) b0.0001
2.60) b0.0001 2.51 (1.72–3.67) b0.0001
Table 5
Multivariate analysis for ACE I/D polymorphism according to dominant, recessive and additive genetic models
ACE I/D Dominant model Recessive model Additive model
Polymorphism Odds ratios (95% CI) P Odds ratios (95% CI) P Odds ratios (95% CI) P
Lone NVAF a 2.87 (1.19–6.89) 0.02 2.01 (1.31–3.09) 0.003 4.47 (2.01–9.92) b0.0001
Variables
Age 0.99 (0.97–1.02) 0.8 1.01 (0.98–1.02) 0.8 1.003 (0.97–1.03) 0.8
Gender 1.42 (80.83–2.46) 0.2 1.15 (0.73–1.89) 0.5 1.27 (0.66–2.46) 0.5
Secondary NVAFb 1.56 (0.95–2.56) 0.07 1.89 (1.32–2.78) 0.001 2.50 (1.57–3.99) b0.0001
Variables
Age 1.02 (0.98–1.03) 0.2 0.99 (0.89–1.01) 0.7 1.003 (0.98–1.02) 0.9
Gender 1.11 (0.74–1.67) 0.6 1.20 (0.78–1.84) 0.3 0.96 (0.61–1.53) 0.9
Hypertension 8.92 (5.97–13.31) b0.0001 11.72 (7.9–17.2) b0.0001 9.22 (5.88–14.44) b0.0001
Diabetes 3.83 (2.02–7.26) b0.0001 4.16 (2.2–7.8) b0.0001 4.02 (1.94–8.33) b0.0001
Smoking habit 2.38 (1.50–3.78) b0.0001 1.84 (1.2–2.9) 0.007 1.81 (1.08–3.02) 0.02
Dyslipidemia 1.96 (81.25–3.07) 0.003 1.19 (0.8–1.7) 0.3 1.25 (0.88–1.78) 0.2
a Adjusted for age, gender.
b Adjusted for age, gender, hypertension, smoking habit and diabetes, ACE I/D polymorphisms, and presence of CAD.
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nonparametric Mann–Whitney test for unpaired data was
used for comparison between single groups. The χ2-test was
used to test for deviation of genotype distribution from
Hardy–Weinberg equilibrium. The association between
ACE I/D polymorphism and NVAF was assessed using
logistic regression analysis under a dominant, recessive and
additive genetic model. The dominant genetic model
compares individuals with one or more polymorphic alleles
with a baseline group with no polymorphic alleles (e.g. ACE
DD+ID vs. II genotype). The recessive genetic model
compares the DD genotype with the combined ID+II
genotypes, which form the baseline group. The additive
genetic model assumes that there is a linear gradient in risk
between the DD, ID and II genotypes (II genotype baseline).
This is equivalent to a comparison of the D allele vs. the I
allele (baseline). All variables that resulted with a p-value
b0.2 in the univariate analysis (hypertension, diabetes,
dyslipidemia, and smoking habit) were introduced into a
multivariable model. Variables as age and gender were also
included into the multivariable model. Odds ratio (OR) withTable 6
ACE ID Polymorphisms and left atrial dimension in lone and secondary
NVAF
Genotype
distribution
Allele
frequency
Lone
NVAF(a)
Lone
NVAF(b)
Secondary
NVAF(c)
Secondary
NVAF(d)
N38 mm b38 mm N38 mm b38 mm
(n=75)
(%)
(n=31)
(%)
(n=352)
(%)
(n=52)
(%)
ACE II 8 (10.7) 1 (0.30) 57 (16.2) 6 (11.5)
ACE ID 35 (46.6) 14 (45.0) 152 (43.2) 18 (34.6)
ACE DD 32 (42.7) 16 (52.0) 143 (40.6) 28 (53.8)
ACE D 0.63 0.74 0.62 0.71
a vs. b allele frequency p=0.19, genotype distribution p=0.4.
c vs. d allele frequency p=0.07, genotype distribution p=0.19.95% confidence interval was determined. Statistical signif-
icance was accepted at p-value b0.05. A sample size of at
least 300 subjects/group was deemed sufficient to prove/
exclude an association between ACE I/D polymorphism and
atrial fibrillation with a statistical power (β) of 90%, and
significance value of 0.05 (α). A sample size of about 300
subjects in each group would limit the β-error of 0.10 (i.e.
the power of the study would be 90%).
3. Results
The demographic and clinical characteristics of the study
population are reported in Tables 1 and 2.
The genotype distribution and allele frequency of the
ACE I/D polymorphism were in agreement with those
predicted by Hardy–Weinberg equilibrium in both patients
and controls. The genotype distribution and allele frequency
of ACE I/D polymorphism are shown in Table 3. The
prevalence of the ACE D allele was 0.65 in NVAF patients,
and 0.52 in controls. The analysis was carried out on the
basis of the different clinical forms of the disease (lone,
n=106 and secondary, n=404), and according to a
dominant, recessive and additive genetic model. We
observed a significant difference in allele frequency, and in
genotype distribution, between NVAF patients and controls
(Table 3); as concerning lone and secondary clinical form,
we found a significant difference in ACE D allele frequency,
but not in genotype distribution (Table 3). The ACE D allele
was associated to the predisposition to lone NVAF under a
dominant, recessive and additive model (Table 4), which
remained significant under the three genetic models after
adjustment for age and gender (Table 5).
As regards to the secondary NVAF, at univariate analysis
we observed a significant association between ACE D allele
and the susceptibility to the disease, under a recessive and
additive, but not dominant, model (Table 4). After
63C. Fatini et al. / International Journal of Cardiology 120 (2007) 59–65adjustment for age, gender, traditional cardiovascular risk
factors and presence of CAD, ACE D allele still remained a
predisposing factor to the disease under the recessive and
additive genetic model (Table 5).
As left atrial dimension is considered, we observed a
higher prevalence of ACE D allele in both lone and
secondary NVAF patients with left atrial dimension
b38 mm, in comparison to that observed in those with left
atrial dimension N38 mm (Table 6).
4. Discussion
This report strengthens previous indications about the role
of ACE I/D polymorphism as a predisposing factor for
NVAF. In the present study ACE I/D polymorphism was
found to be associated with both lone and secondary NVAF,
providing support for its investigation in evaluating the
susceptibility to the disease.
These findings are consistent with the observation of the
involvement of RAS in NVAF. An increased ACE activity,
and consequently increased angiotensin II levels, may cause
electrophysiological alterations via different mechanisms. In
particular, extensive interstitial fibrosis is an important
pathophysiological substrate of AF. Angiotensin II can
induce the proliferation and differentiation of fibroblasts
through the involvement of extracellular signal-regulated
kinases proteins [21]. Moreover, angiotensin II can contrib-
ute to cell differentiation and fibroblast activation by the
involvement of other protein kinases like cJun-N-terminal
kinase or p38 mitogen activated protein kinase [22].
Angiotensin II may also induce the development of
interstitial fibrosis by stimulating collagen synthesis and
inhibiting collagenase activity [23]. Furthermore, the ability
of angiotensin II to stimulate fibroblasts and alter the
metabolism of fibrillar collagen may be mediated by
transforming growth factor-β1, endothelin-1, and plasmino-
gen activator inhibitor-1 [24], and experimental studies
provided evidence that osteopontin represented a critical
mediator of the proinflammatory and profibrotic effects
[25,26]. Data from experimental and clinical studies [27,28]
reported a role for ACE I/D polymorphism in influencing
interstitial fibrosis. Really, it has been demonstrated, in a
genetic rat model, a different development of cardiac fibrosis
in relation to different ACE I/D polymorphism genotypes, in
particular rats with high ACE plasma levels with ACE DD
genotype, have more accumulation of collagen I and
fibronectin in comparison to animals with low plasma
ACE activity, and the other two genotypes [25]. According-
ly, data from patients with untreated essential hypertension,
have demonstrated the association between ACE DD
genotype and elevated serum carboxy-terminal propeptide
of procollagen type I (PICP), a marker of myocardial
fibrosis, concentration, thus proposing a link between the
ACE DD genotype and myocardial fibrosis in humans [26].
The observation that ACE D allele does not influence the
left atrial dimension in both lone and secondary NVAF, leadsus to hypothesize that the real mechanism by which this gene
influences the predisposition to the disease, lies in the
profibrotic effect of angiotensin II on cardiac tissue. In
particular, the datum of a higher, but not significant,
prevalence of ACE D allele in NVAF patients with left atrial
dimension b38 mm, in comparison to that observed in those
with left atrial dilation, supports this hypothesis.
The results from the current study are in keeping with our
previous report [14], and underline the role of the ACE gene
in modulating the susceptibility to both lone and secondary
NVAF in a larger population. Actually, in our study the
number of subjects investigated was sufficient to detect
absolute differences in allele frequency, with a statistical
power of 90% (β=0.9) and a significance value of 0.05 (α).
Recently a role for multiple RAS genes in the development of
nonfamilial structural AF has been suggested [29]. Our
findings are at variance with those of Tsai et al. [29], who
found an association between AF and the ACE I/D
polymorphism only in a subclass of patients with specific
angiotensinogen gene variants, and with valvular disease.
These conflicting results may be due to the different
prevalence of the ACE D allele, probably related to the
different genetic background of the study populations.
Moreover, our patients had no valvular disease, and we
analyzed patients with both lone and secondary AF. Control
subjects in the study of Tsai et al. did not consist of healthy
individuals, but rather of patients with diabetes, hypertension,
or CAD and the only difference was the presence or absence
of AF.
Recently, a prospective study by Zaman et al. [30]
explored the role of ACE-inhibitors in facilitating cardiover-
sion of persistent AF, and reported that the use of long-term
therapy facilitated electrical defibrillation in persistent AF
patients. Our findings suggest that ACE I/D polymorphism
determination may be used as a guide to identify AF subjects
who are most likely to benefit from pharmacological
treatment with ACE-inhibitors. There is evidence that
responses to drugs are, at least partially, under genetic
control [31]; therefore the growing need for better identify-
ing people who have the highest benefit from pharmacolog-
ical interventions and the lowest risk of developing side-
effects, assumes that pharmacogenetic, which explores the
individual response to a particular drug, may significantly
assist in choosing the adequate drug.
The clinical implication of our results is mainly related to
the physiopathological meaning of these findings; really, the
ACE D allele modulates angiotensin II levels, so contribut-
ing to the cardiac remodeling and to the development of
atrial fibrillation. Pharmacological inhibition of the ACE
appears to reduce atrial structural remodeling, and prevent
the loss of atrial microcapillaries [32]. Moreover, data from a
recent meta-analysis [33] reported that the use of ACE-
inhibitors and ARBs following cardioversion, appears
promising in the prevention of atrial fibrillation.
This study has two limitations. First, the control group
was composed of apparently healthy subjects very seldom
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quite different from the patient group. One could hypothesize
that the ACE D allele influences susceptibility to either
diabetes or hypertension, or both; nevertheless, the observa-
tion that the ACE D allele is associated with lone NVAF
strongly supports the genetic relevance in the pathogenesis
of this condition. The second limitation lies in lack of
information about serum ACE levels. The ACE D allele has
been reported to be associated with increased serum levels of
circulating enzyme in both healthy subjects [5], and in
coronary artery disease [34], thus modulating angiotensin II
availability. Actually, this study provides evidence of the
association between ACE D allele and NVAF, but it does not
demonstrate the direct mechanism by which ACE I/D
polymorphism causes the disease.
In summary, this study highlights the role of ACE gene in
predisposing to both lone and secondary NVAF, thus
contributing to investigate the molecular mechanisms respon-
sible for this complex condition. Therefore, the clinical
relevance of our findings lies on the one hand in the possible
characterization of subjects predisposed to NVAF in the
absence of traditional risk factors, and on the other hand in the
use of ACE-inhibitors therapy, thus improving the arrhythmo-
genic substrate. It will be intriguing to verify the hypothesis of
a role of the ACE I/D polymorphism as a genetic determinant
of response to ACE in AF.
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